<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648739</url>
  </required_header>
  <id_info>
    <org_study_id>C07-003</org_study_id>
    <nct_id>NCT00648739</nct_id>
  </id_info>
  <brief_title>Safety and Dose Ranging Study of ALXN6000 to Treat Relapsing or Refractory CLL or MM</brief_title>
  <official_title>A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and best dose of ALXN6000 in treating
      relapsing or refractory B-CLL or MM and to study how ALXN6000 may help the immune system
      fight cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Obtain dose, safety, PK, and PD information about ALXN6000.</measure>
    <time_frame>From first dose through 10 weeks after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obtain biological information on ALXN6000 including binding to CD200 on B CLL cells; describe the effect of ALXN6000 in B-CLL patients on ORR and its components of CR, PR, nPR and SD; and in MM patients on response as defined in the protocol</measure>
    <time_frame>From first dose through 10 weeks after the last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1, 2, 3, 4, 5, 6, and 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALXN6000 dose ranging cohorts numbered 1-7 with dosages of 50 mg/m2 to 600 mg/m2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN6000</intervention_name>
    <description>Part A is a comparison of different dosages of ALXN6000 by cohort ranging from 50 mg/m2 up to 600 mg/m2 given as a single IV dose. Once the most appropriate dose is determined it will be given over a 28 day cycle for 4 cycles in Part B Cohort 1 = 50 mg/m2 Cohort 2 = 100 mg/m2 Cohort 3 = 200 mg/m2 Cohort 4 = 300 mg/m2 Cohort 5 = 400 mg/m2 Cohort 6 = 500 mg/m2</description>
    <arm_group_label>1, 2, 3, 4, 5, 6, and 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing or Refractory B CLL or MM

          -  ECOG performance status 0-2

          -  Anticipated survival of greater than 6 months.

          -  Female patients of childbearing potential must agree to use two forms of contraception

          -  Patients must have a standard indication for treatment of their malignancy

          -  Is willing and able to give written informed consent.

        Exclusion Criteria:

          -  Absolute neutrophil count (ANC) &lt; 1000 x 109/L

          -  Platelet count &lt; 50,000 x 109/L

          -  Pregnant or lactating women.

          -  Prior history of autoimmune hemolysis requiring therapy.

          -  Prior history of immune thrombocytopenia.

          -  Active autoimmune disease requiring immunosuppressive therapy.

          -  Positive Coombs' Test (neither Direct or Indirect)

          -  Ongoing corticosteroid treatment equivalent to the mineralocortacoid potency of 10
             milligram (mg) /day of prednisone, or greater, for any condition.

          -  Prior stem cell transplantation within 4 weeks prior to enrollment.

          -  Prior chemotherapy for the applicable malignancy within 30 days of enrollment.

          -  Neurosurgery or cranial radiation therapy within one year of enrollment.

          -  Clinically significant renal, hepatic or heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leonard Heffner</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Duruka Mahadevan</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles Farber</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOANNJ-Carol G. Simon Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Moshe Talpaz</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Lanasa</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center at UMC North</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Assoc. of Northern NJ Carol G. Simon Cancer Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <disposition_first_submitted>January 27, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>January 27, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 30, 2017</disposition_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell Chronic Lymphocytic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Multiple Myeloma</keyword>
  <keyword>CD200</keyword>
  <keyword>Anti-CD200</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

